R&G Pharmastudies301333.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, R&G Pharmastudies (301333.SZ) trades at a P/E of 44.40x, P/B of 2.68x, P/S of 5.70x, and a dividend yield of 0.29%.
Longitudinal percentile comparison: P/E sits at the 69th percentile over the trailing 10Y window (vs. 77th percentile over 3Y); P/B sits at the 31st percentile over the trailing 10Y window (vs. 40th percentile over 3Y); P/S sits at the 13th percentile over the trailing 10Y window (vs. 18th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 56th percentile within its industry and the 57th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.29%, ranking at the 46th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 38.1 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. R&G Pharmastudies operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 301333 · SZSE: 301333 · 301333
Want the full picture on whether R&G Pharmastudies (301333.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 44.40 | ||||||
| P/B (MRQ) | 2.68 | ||||||
| P/S (TTM) | 5.70 | ||||||
| Dividend Yield | 0.29% | ||||||
| Buyback + Div Yield | 0.29% |